The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
|Videos|May 25, 2017
Dr. Badani on the Benefits of Robotic Surgery for Kidney Cancer
Author(s)Ketan K. Badani, MD
Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the benefits of performing a partial robotic nephrectomy for patients with kidney cancer.
Advertisement
Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the benefits of performing a partial robotic nephrectomy for patients with kidney cancer.
Having a minimally invasive surgery gives patients a quicker recovery time with less pain involved, explains Badani.
Additionally, the surgery is able to protect normal kidney function, which benefits the kidney over a longer period of time, states Badani.
Advertisement
Related to this article
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5